Patient compliance and text messaging

Article

A clinical trial assessing glaucoma treatment compliance of patients using text and telephone messaging technology has been launched by the Wilmer Eye Institute at Johns Hopkins University, Baltimore, Maryland, US.

A clinical trial assessing glaucoma treatment compliance using text and telephone messaging technology has been launched by the Wilmer Eye Institute at Johns Hopkins University, Baltimore, Maryland, US.

The technology has been developed by US firm MEMOTEXT to increase the adherence of glaucoma patients to their prescribed medication. Michael V. Boland, MD, PhD will run the 14-month study of 500 patients, which aims to increase patient compliance through text message and telephone reminders to take medication. Of the 500 participants, around 100 will be randomized to be included in the programme to increase adherence through technology; the remaining patients will be monitored for adherence to their glaucoma medications. The study is expected to be completed by mid-2010.

The study, “The Impact of Automated Dosing Reminders on Medication Adherence using HealthVault” is funded by Microsoft’s Be Well Fund.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.